Aponermin or placebo in combination with thalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (CPT-MM301) : a randomised, double-blinded, placebo-controlled, phase 3 trial
© 2023. BioMed Central Ltd., part of Springer Nature..
BACKGROUND: Aponermin, a circularly permuted tumor necrosis factor-related apoptosis-inducing ligand, is a potential death receptor 4/5-targeted antitumour candidate. Previous phase 1/2 studies have demonstrated the efficacy of aponermin in patients with relapsed or refractory multiple myeloma (RRMM). To confirm the superiority of aponermin plus thalidomide and dexamethasone (aponermin group) over placebo plus thalidomide and dexamethasone (placebo group) in RRMM, a randomized, double-blinded, placebo controlled phase 3 trial was performed.
METHODS: Four hundred seventeen patients with RRMM who had previously received at least two regimens were randomly assigned (2:1) to receive aponermin, thalidomide, and dexamethasone or placebo, thalidomide, and dexamethasone. The primary endpoint was progression-free survival (PFS). Key secondary endpoints included overall survival (OS) and overall response rate (ORR).
RESULTS: A total of 415 patients received at least one dose of trial treatment (276 vs. 139). The median PFS was 5.5 months in the aponermin group and 3.1 months in the placebo group (hazard ratio, 0.62; 95% confidence interval [CI], 0.49-0.78; P < 0.001). The median OS was 22.4 months for the aponermin group and 16.4 months for the placebo group (hazard ratio, 0.70; 95% CI, 0.55-0.89; P = 0.003). Significantly higher rates of ORR (30.4% vs. 13.7%, P < 0.001) and very good partial response or better (14.1% vs. 2.2%, P < 0.0001) were achieved in the aponermin group than in the placebo group. Treatment with aponermin caused hepatotoxicity in some patients, as indicated by the elevated alanine transaminase, aspartate transaminase, or lactate dehydrogenase levels (52.2% vs. 24.5%, 51.1% vs. 19.4% and 44.9% vs. 21.6%, respectively), mostly grade 1/2, transient and reversible. The main grade 3/4 adverse events included neutropenia, pneumonia and hyperglycemia. The incidence of serious adverse events was similar between the two groups (40.6% vs. 37.4%). There was no evidence that aponermin leads to hematological toxicity, nephrotoxicity, cardiotoxicity, or secondary tumors.
CONCLUSIONS: Aponermin plus thalidomide and dexamethasone significantly improved PFS, OS and ORR with manageable side effects in RRMM patients who had received at least two prior therapies. These results support the use of aponermin, thalidomide, and dexamethasone as a treatment option for RRMM patients.
TRIAL REGISTRATION: The trial was registered at http://www.chictr.org.cn as ChiCTR-IPR-15006024, 17/11/2014.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
BMC cancer - 23(2023), 1 vom: 14. Okt., Seite 980 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Xia, Zhongjun [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 23.10.2023 Date Revised 20.11.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1186/s12885-023-11489-8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363316264 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363316264 | ||
| 003 | DE-627 | ||
| 005 | 20231226093059.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12885-023-11489-8 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1210.xml |
| 035 | |a (DE-627)NLM363316264 | ||
| 035 | |a (NLM)37838670 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Xia, Zhongjun |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Aponermin or placebo in combination with thalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (CPT-MM301) |b a randomised, double-blinded, placebo-controlled, phase 3 trial |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.10.2023 | ||
| 500 | |a Date Revised 20.11.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. BioMed Central Ltd., part of Springer Nature. | ||
| 520 | |a BACKGROUND: Aponermin, a circularly permuted tumor necrosis factor-related apoptosis-inducing ligand, is a potential death receptor 4/5-targeted antitumour candidate. Previous phase 1/2 studies have demonstrated the efficacy of aponermin in patients with relapsed or refractory multiple myeloma (RRMM). To confirm the superiority of aponermin plus thalidomide and dexamethasone (aponermin group) over placebo plus thalidomide and dexamethasone (placebo group) in RRMM, a randomized, double-blinded, placebo controlled phase 3 trial was performed | ||
| 520 | |a METHODS: Four hundred seventeen patients with RRMM who had previously received at least two regimens were randomly assigned (2:1) to receive aponermin, thalidomide, and dexamethasone or placebo, thalidomide, and dexamethasone. The primary endpoint was progression-free survival (PFS). Key secondary endpoints included overall survival (OS) and overall response rate (ORR) | ||
| 520 | |a RESULTS: A total of 415 patients received at least one dose of trial treatment (276 vs. 139). The median PFS was 5.5 months in the aponermin group and 3.1 months in the placebo group (hazard ratio, 0.62; 95% confidence interval [CI], 0.49-0.78; P < 0.001). The median OS was 22.4 months for the aponermin group and 16.4 months for the placebo group (hazard ratio, 0.70; 95% CI, 0.55-0.89; P = 0.003). Significantly higher rates of ORR (30.4% vs. 13.7%, P < 0.001) and very good partial response or better (14.1% vs. 2.2%, P < 0.0001) were achieved in the aponermin group than in the placebo group. Treatment with aponermin caused hepatotoxicity in some patients, as indicated by the elevated alanine transaminase, aspartate transaminase, or lactate dehydrogenase levels (52.2% vs. 24.5%, 51.1% vs. 19.4% and 44.9% vs. 21.6%, respectively), mostly grade 1/2, transient and reversible. The main grade 3/4 adverse events included neutropenia, pneumonia and hyperglycemia. The incidence of serious adverse events was similar between the two groups (40.6% vs. 37.4%). There was no evidence that aponermin leads to hematological toxicity, nephrotoxicity, cardiotoxicity, or secondary tumors | ||
| 520 | |a CONCLUSIONS: Aponermin plus thalidomide and dexamethasone significantly improved PFS, OS and ORR with manageable side effects in RRMM patients who had received at least two prior therapies. These results support the use of aponermin, thalidomide, and dexamethasone as a treatment option for RRMM patients | ||
| 520 | |a TRIAL REGISTRATION: The trial was registered at http://www.chictr.org.cn as ChiCTR-IPR-15006024, 17/11/2014 | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Clinical Trial, Phase III | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Aponermin | |
| 650 | 4 | |a Multiple myeloma | |
| 650 | 4 | |a Phase 3 | |
| 650 | 4 | |a Relapsed/refractory | |
| 650 | 4 | |a TNF-related apoptosis-inducing ligand | |
| 650 | 7 | |a Thalidomide |2 NLM | |
| 650 | 7 | |a 4Z8R6ORS6L |2 NLM | |
| 650 | 7 | |a Dexamethasone |2 NLM | |
| 650 | 7 | |a 7S5I7G3JQL |2 NLM | |
| 700 | 1 | |a Leng, Yun |e verfasserin |4 aut | |
| 700 | 1 | |a Fang, Baijun |e verfasserin |4 aut | |
| 700 | 1 | |a Liang, Yang |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Fu, Chengcheng |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Linhua |e verfasserin |4 aut | |
| 700 | 1 | |a Ke, Xiaoyan |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Hua |e verfasserin |4 aut | |
| 700 | 1 | |a Weng, Jianyu |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Li |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Yaozhong |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Xuejun |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Zhongxia |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Aichun |e verfasserin |4 aut | |
| 700 | 1 | |a Shi, Qingzhi |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Yuhuan |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Xiequn |e verfasserin |4 aut | |
| 700 | 1 | |a Pan, Ling |e verfasserin |4 aut | |
| 700 | 1 | |a Cai, Zhen |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Zhao |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Yafei |e verfasserin |4 aut | |
| 700 | 1 | |a Fan, Yaqun |e verfasserin |4 aut | |
| 700 | 1 | |a Hou, Ming |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Yigai |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, Jianda |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Jianfeng |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Xiaohong |e verfasserin |4 aut | |
| 700 | 1 | |a Meng, Haitao |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Xuzhang |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Fei |e verfasserin |4 aut | |
| 700 | 1 | |a Ren, Hanyun |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Bintao |e verfasserin |4 aut | |
| 700 | 1 | |a Shao, Zonghong |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Hebing |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Shifang |e verfasserin |4 aut | |
| 700 | 1 | |a Zheng, Xiangjun |e verfasserin |4 aut | |
| 700 | 1 | |a Wei, Peng |e verfasserin |4 aut | |
| 700 | 1 | |a Pang, Hongyan |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Yuzhang |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Sujun |e verfasserin |4 aut | |
| 700 | 1 | |a Yan, Lingzhi |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Yanping |e verfasserin |4 aut | |
| 700 | 1 | |a Jing, Hongmei |e verfasserin |4 aut | |
| 700 | 1 | |a Du, Juan |e verfasserin |4 aut | |
| 700 | 1 | |a Ling, Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Jingyi |e verfasserin |4 aut | |
| 700 | 1 | |a Sui, Weiwei |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Fuxu |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Xin |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Wenming |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMC cancer |d 2001 |g 23(2023), 1 vom: 14. Okt., Seite 980 |w (DE-627)NLM111431948 |x 1471-2407 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2023 |g number:1 |g day:14 |g month:10 |g pages:980 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12885-023-11489-8 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2023 |e 1 |b 14 |c 10 |h 980 | ||